Ginkgo biloba in the treatment of ADHD

Ginkgo biloba in the treatment of ADHD in child and adolescent: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138711151556N6

Enrollment

Registered

2009-03-13

Start date

2007-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disturbance of activity and attention. Disturbance of activity and attention

Interventions

Intervention 1: Tablet Ginkgo Biloba 80 mg/day as intervention group for 6 weeks. Intervention 2: Tablet Ritalin 20-30 mg/kg/day for 6 weeks as control group.

Treatment - Drugs

Tablet Ginkgo Biloba 80 mg/day as intervention group for 6 weeks

Tablet Ritalin 20-30 mg/kg/day for 6 weeks as control group

Eligibility

Sex/Gender

All

Age

6 Years to 17 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Diagnosis of ADHD based on DSMIV age between 6-17 Exclusion Criteria: receiving of any psychotropics drugs during past two weeks, presence of any psychiatric disorders or mental retardation (I.Q. <70) except for ODD, History of Allergy to Ginkgo, presence of any medical problem including cardiovascular dieseases, presence of uncontrolled seizures

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of ADHD. Timepoint: Week 0 (before treatment) and Weeks 3 and 6 after treatment. Method of measurement: Teacher and Parent ADHD Rating Scale.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026